Ivermectin to reduce malaria transmission II. Considerations regarding clinical development pathway

Vista senzilla d'ítem
dc.contributor.authorChaccour, Carlos
dc.contributor.authorRabinovich, Regina
dc.date.accessioned2017-05-10T13:26:31Z
dc.date.available2017-05-10T13:26:31Z
dc.date.issued2017-04-24
dc.date.updated2017-05-03T18:01:50Z
dc.description.abstractThe development of ivermectin as a complementary vector control tool will require good quality evidence. This paper reviews the different eco-epidemiological contexts in which mass drug administration with ivermectin could be useful. Potential scenarios and pharmacological strategies are compared in order to help guide trial design. The rationale for a particular timing of an ivermectin-based tool and some potentially useful outcome measures are suggested.
dc.format.extent13 p.
dc.format.mimetypeapplication/pdf
dc.identifier.issn1475-2875
dc.identifier.pmid28434405
dc.identifier.urihttps://hdl.handle.net/2445/110769
dc.language.isoeng
dc.publisherBiomed Central
dc.relation.isformatofReproducció del document publicat a: http://dx.doi.org/10.1186/s12936-017-1802-3
dc.relation.ispartofMalaria Journal, 2017, vol. 16, num. 1, p. 166
dc.relation.urihttp://dx.doi.org/10.1186/s12936-017-1802-3
dc.rightscc by (c) Chaccour et al., 2017
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es/
dc.sourceArticles publicats en revistes (ISGlobal)
dc.subject.classificationMalària
dc.subject.classificationAssaigs clínics
dc.subject.otherMalaria
dc.subject.otherClinical trials
dc.titleIvermectin to reduce malaria transmission II. Considerations regarding clinical development pathway
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:eu-repo/semantics/publishedVersion

Fitxers

Paquet original

Mostrant 1 - 1 de 1
Miniatura
Nom:
chaccour2017_2515.pdf
Mida:
1.02 MB
Format:
Adobe Portable Document Format
Descarregar

Col·leccions

Articles publicats en revistes (ISGlobal)